|
| Thursday, March 4, 2021 |
|
|
APOLLOMICS(冠科美博)UPROLESELAN注射液(APL-106)中国I期临床试验第一例受试者成功入组 |
| Apollomics, Inc.(冠科美博)，一家致力于发现和开发肿瘤靶向和免疫新药及其组合疗法的创新生物制药公司，今天宣布，Uproleselan注射液(APL-106)用于治疗成人复发或难治性急性髓系白血病的中国I期临床试验第一例受试者成功入组。 more info >> |
|
|
APOLLOMICS(冠科美博)UPROLESELAN注射液(APL-106)中國I期臨床試驗第一例受試者成功入組 |
| Apollomics, Inc.(冠科美博)，一家致力於發現和開發腫瘤靶向和免疫新藥及其組合療法的創新生物製藥公司，今天宣佈，Uproleselan注射液(APL-106)用於治療成人復發或難治性急性髓系白血病的中國I期臨床試驗第一例受試者成功入組。 more info >> |
|
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. In February of this year, the two Phase 1 study sites were initiated. more info >> |
|
| Friday, February 12, 2021 |
|
|
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa. more info >> |
|
|
APOLLOMICS(冠科美博)在中國和南非引進一款靶向主動免疫檢查點控制劑重組疫苗 |
| more info >> |
|
|
APOLLOMICS(冠科美博)在中国和南非引进一款靶向主动免疫检查点控制剂重组疫苗 |
| Apollomics, Inc.(冠科美博)，一家致力于发现和开发肿瘤靶向和免疫新药及其组合疗法的创新生物制药公司，今天宣布一份独家许可协议，根据协议，冠科美博获得TYG100在中国(中国大陆、香港、澳门和台湾)和南非的开发和商业化权利。 more info >> |
|
| Thursday, February 11, 2021 |
|
|
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China |
| Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, today announced an exclusive collaboration and license agreement for the development and commercialization of tegavivint in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China. more info >> |
|
|
APOLLOMICS(冠科美博)從ITERION THERAPEUTICS引進TEGAVIVINT |
| Apollomics, Inc.(冠科美博)，一家致力於發現和開發腫瘤靶向和免疫新藥及其組合療法的創新生物製藥公司，和Iterion Therapeutics, Inc., 一家致力於開發創新腫瘤療法的臨床階段生物技術公司，今天宣佈，雙方就Tegavivint在中國(中國大陸、香港、澳門和台灣)的開發和商業化達成獨家合作與許可協議。 more info >> |
|
|
APOLLOMICS(冠科美博)从ITERION THERAPEUTICS引进TEGAVIVINT |
| more info >> |
|
| Wednesday, February 10, 2021 |
|
|
APOLLOMICS(冠科美博)从EDISON ONCOLOGY引进一款创新实体瘤酪氨酸蛋白激酶抑制剂 |
| 2021年2月9日，中国杭州市、美国福斯特市和门洛帕克报道，Apollomics, Inc. (冠科美博)，一家致力于发现和开发肿瘤靶向和免疫新药及其组合疗法的创新生物制药公司，和Edison Oncology Holding Corp., 今天宣布，冠科美博获得EO1001全球(中国大陆、香港和台湾除外) 开发和商业化权利。 more info >> |
|
|
|
|
